PLoS ONE (Jan 2022)

Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog

  • Yoshihito Uchida,
  • Masamitsu Nakao,
  • Shunsuke Yamada,
  • Shohei Tsuji,
  • Hayato Uemura,
  • Jun-ichi Kouyama,
  • Kayoko Naiki,
  • Kayoko Sugawara,
  • Nobuaki Nakayama,
  • Yukinori Imai,
  • Tomoaki Tomiya,
  • Satoshi Mochida

Journal volume & issue
Vol. 17, no. 2

Abstract

Read online

Background To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. Methods A total of 103 patients with serum HBsAg levels of ≥100 IU/mL who had received ETV were enrolled. The nucleos(t)ide analog used for the treatment was switched from ETV to TAF, and the changes in serum HBsAg levels during the 144-week period before and after the drug switching were compared in 74 patients who had received ETV at least for 192 weeks. Results Significant decreases of serum HBsAg levels were observed during both the ETV and the TAF administration period, although the degree of reduction was greater during the latter period than during the former period (PConclusion Switching of the nucleos(t)ide analog used for treatment from ETV to TAF merits consideration in patients with chronic HBV infection, since the extent of reduction of the serum HBsAg level was greater during the TAF treatment period than during the ETV treatment period.